Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (ChiCTR2500114713) titled 'A prospective, randomized, controlled clinical study on the treatment of patients with decompensated chronic heart failure and diuretic resistance with recombinant human brain natriuretic peptide' on Dec. 17, 2025.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: Tianjin Chest Hospital
Condition:
Acute decompensation of chronic heart failure
Intervention:
Conventional-dose recombinant human brain natriuretic peptide group:Conventional dose group: On the basis of conventional treatment, recombinant human brain natriuretic peptide at a dose of 0.0075-0.01µg/kg·min was contin...